Peripheral blood biomarkers and 28-d ICU mortality.

<p>^a Includes MICU and cardiac ICU patients.</p><p>^b<i>p</i>-Value using risk categories in increments of 10% from 0%–100%. In all cases the NRI value refers to the addition of the noted biomarker to the clinical model (including age, gender, race/ethnicity, APACHE II score, and sepsis) and additional biomarkers, where indicated.</p>c<p>Elevated mtDNA level represents NADH dehydrogenase 1 DNA copy number of ≥3,200 copies/µl plasma compared to those with <3,200 copies/µl.</p>d<p>Clinical model includes age, gender, race/ethnicity, APACHE II score <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001577#pmed.1001577-Knaus1" target="_blank">[20]</a>, and sepsis.</p>e<p>The effect of procalcitonin on the mortality is no longer significant after adjusting for an elevated mtDNA level (OR 1.01, 95% CI 0.99–1.02, <i>p</i> = 0.42).</p>f<p>The effect of lactate on the mortality is attenuated after adjusting for an elevated mtDNA level (OR 1.2, 95% CI 0.99–1.51, <i>p</i> = 0.05).